Platinum-sensitive Ovarian Cancer research hub

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

This study looks at new treatments for recurrent ovarian cancer that has responded to previous platinum-based chemotherapy. It compares a vaccine (OSE2101) alone, or with another drug (Pembrolizumab), against standard supportive care to see if they can delay the cancer returning.